The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 07, 2015

Filed:

Apr. 18, 2007
Applicants:

Erich Hoffmann, Memphis, TN (US);

Scott L. Krauss, Millington, TN (US);

Mahesh Kumar, Fort Dodge, IA (US);

Richard J. Webby, Memphis, TN (US);

Robert G. Webster, Memphis, TN (US);

Inventors:

Erich Hoffmann, Memphis, TN (US);

Scott L. Krauss, Millington, TN (US);

Mahesh Kumar, Fort Dodge, IA (US);

Richard J. Webby, Memphis, TN (US);

Robert G. Webster, Memphis, TN (US);

Assignees:

St. Jude Children's Research Hospital, Memphis, TN (US);

Zoetis Services LLC, Florham Park, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 49/00 (2006.01); A01N 63/00 (2006.01); A61K 39/12 (2006.01); A61K 39/145 (2006.01); A61K 47/00 (2006.01); C07K 14/005 (2006.01); A61K 35/12 (2015.01); A61K 39/39 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/145 (2013.01); C07K 14/005 (2013.01); A61K 49/0004 (2013.01); A61K 35/12 (2013.01); A61K 39/39 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/552 (2013.01); A61K 2039/55566 (2013.01); C12N 2760/16134 (2013.01); A61K 39/12 (2013.01); A61K 2039/70 (2013.01);
Abstract

A vaccine composition and method which is effective in preventing or ameliorating Avian Influenza Virus infection is set forth herein. The vaccine contains at least two inactivated strains of avian influenza virus, wherein the combined hemagglutinin (HA) total is at least about 200 HA/dose of the vaccine composition, and wherein each of the strains presents at least about 128 HA/dose, and further wherein one of the strains has the same HA subtype as that of a challenge virus, and wherein at least one of the strains has a different NA subtype than the challenge virus.


Find Patent Forward Citations

Loading…